Nocturne Acquisition Corporation

Status: Liquidated

U=S+R R=S/10

IPO Proceeds, $M	$115.00M
IPO Date	Mar 31, 2021
CEO	Henry Monzon
Left Lead	Chardan
IPO Cash in Trust	101.0%
SPAC Tenor	12 + 3 + 3 + 6 + 9 + 6
IPO Sector	Technology Disruptive technology companies that focus on blockchain/crypto and artificial intelligence
IPO Geography	Global
Target Company	N/A
Deal Announced	N/A
Deal Size, $M	TBD
Deal Sector	TBD
Deal Geography	TBD
SEC Filings	www.sec.gov
Approval Vote	TBD
Amendment Vote	Feb 22, 2024
Closing Date	Apr 19, 2024

MBTC MBTCU MBTCR

Price
Volume, 3-month avg.	N/A

Price
Volume, today
Volume, 3-month avg.	N/A

Price
Volume, today
Volume, 3-month avg.	N/A

Price
Volume, today
Volume, 3-month avg.	N/A

No credit card required

Structure and cap table
8 directors & officers
53 filings and events
2 underwriters

Structure

Sign in to view structure, cap table, and calendar of events.

Team

Name	Age	Title
Henry Monzon	48	Chairman and Chief Executive Officer
Ka Seng (Thomas) Ao	31	Chief Financial Officer and Director
Etienne Snyman	38	Director
Simon Choi	61	Independent Director
Haoyu (Liz) Lin	35	Chief Strategy Officer and Director
Derek Yiyi Feng	55	Director
Ka Lok (Ivan) Wong	45	Director
Giuseppe Mangiacotti	33	Director

Sign in to view team biographies and more sponsor and affiliate data.

Advisors

Underwriters
Chardan	BR	9,950,000	units
B. Riley FBR		50,000
		10,000,000	units
	Up-Front UW fee	2.00	%
	Deferred UW fee	3.50	%

Sign in to view more advisor data.

Filings


Feb 8, 2021	Initial S-1
Feb 23, 2021	Amended S-1 Sign In to view filing content.
Mar 26, 2021	POS AM Post-effective amendment to S-1 Sign In to view filing content.
Mar 31, 2021	PR announcing pricing of $100mm IPO Sign In to view filing content.
Apr 1, 2021	424B4 IPO Prospectus
Apr 15, 2021	8-K announcing full over-allotment exercise Sign In to view filing content.
Apr 29, 2021	8-K announcing separate trading of shares and warrants Sign In to view filing content.
Dec 20, 2021	8-K announcing change in directors Sign In to view filing content.
Jan 11, 2022	8-K announcing change in directors Sign In to view filing content.
Apr 5, 2022	8-K announcing sponsor contribution to trust in connection with extension Sign In to view filing content.
Jul 5, 2022	8-K announcing sponsor contribution to trust in connection with extension Sign In to view filing content.
Aug 22, 2022	PRE14A Preliminary proxy for charter extension meeting Sign In to view filing content.
Sep 2, 2022	DEF14A Definitive proxy for charter extension meeting Sign In to view filing content.
Oct 5, 2022	8-K with extension meeting results Sign In to view filing content.
Oct 21, 2022	8-K/A with correction to extension meeting results Sign In to view filing content.
Jan 3, 2023	PR announcing business combination with Cognos Therapeutics Sign In to view filing content.
Jan 4, 2023	8-K with full Cognos Therapeutics merger agreement Sign In to view filing content.
Feb 23, 2023	PRE14A Preliminary Proxy for charter extension meeting Sign In to view filing content.
Mar 8, 2023	DEF14A Definitive Proxy for charter extension meeting Sign In to view filing content.
Mar 31, 2023	DEFA14A supplement to definitive proxy for charter amendment meeting Sign In to view filing content.
Apr 3, 2023	8-K with trust account update and redemption update Sign In to view filing content.
Apr 6, 2023	8-K with extension meeting results Sign In to view filing content.
Apr 14, 2023	8-K with Investor Presentation Sign In to view filing content.
Aug 15, 2023	S-4 registration statement containing preliminary proxy for Cognos Therapeutics business combination Sign In to view filing content.
Sep 6, 2023	8-K with updated investor presentation Sign In to view filing content.
Sep 20, 2023	PR announcing engagement of Chardan as capital markets advisor Sign In to view filing content.
Sep 29, 2023	8-K announcing intention to extend charter Sign In to view filing content.
Oct 4, 2023	S-4/A Amendment #1 to registration statement containing preliminary proxy for Cognos Therapeutics business combination Sign In to view filing content.
Oct 5, 2023	8-K with amendment#1 to Cognos Therapeutics merger agreement Sign In to view filing content.
Oct 17, 2023	8-K with updated investor presentation Sign In to view filing content.
Nov 6, 2023	425 with update on intended merger target - Cognos Therapeutics Sign In to view filing content.
Nov 13, 2023	S-4/A Amendment #2 to registration statement containing preliminary proxy for Cognos Therapeutics business combination Sign In to view filing content.
Nov 28, 2023	8-K announcing intention to extend charter Sign In to view filing content.
Nov 29, 2023	PRE14A Preliminary Proxy for charter extension meeting Sign In to view filing content.
Dec 11, 2023	DEF14A Definitive Proxy for charter extension meeting Sign In to view filing content.
Dec 19, 2023	S-4/A Amendment #3 to registration statement containing preliminary proxy for Cognos Therapeutics business combination Sign In to view filing content.
Dec 29, 2023	S-4/A Amendment #4 to registration statement containing preliminary proxy for Cognos Therapeutics business combination Sign In to view filing content.
Jan 4, 2024	8-K with extension meeting results Sign In to view filing content.
Jan 5, 2024	424B3 Definitive proxy for Cognos Therapeutics business combination Sign In to view filing content.
Jan 22, 2024	424B3 Supplement to definitive proxy for Cognos Therapeutics business combination
Jan 26, 2024	PRE14A Preliminary Proxy for NTA Requirement Amendment meeting Sign In to view filing content.
Jan 30, 2024	8-K announcing postponement of Cognos Therapeutics approval meeting Sign In to view filing content.
Jan 31, 2024	8-K announcing intention to extend charter Sign In to view filing content.
Feb 5, 2024	8-K announcing postponement of Cognos Therapeutics approval meeting Sign In to view filing content.
Feb 5, 2024	DEF14A Definitive Proxy for NTA Requirement Amendment meeting Sign In to view filing content.
Feb 7, 2024	8-K announcing change in Directors Sign In to view filing content.
Feb 12, 2024	POS AM Post-effective Amendment to registration statement Sign In to view filing content.
Feb 15, 2024	424B3 Definitive proxy for Cognos Therapeutics business combination Sign In to view filing content.
Feb 26, 2024	8-K announcing postponement of Cognos Therapeutics business combination and confirming funding of extension payment Sign In to view filing content.
Feb 28, 2024	8-K with NTA Requirement Amendment meeting results Sign In to view filing content.
Mar 19, 2024	8-K announcing postponement of Cognos Therapeutics approval meeting Sign In to view filing content.
Apr 1, 2024	8-K announcing expiration of merger agreement and cancellation of Cognos Therapeutics approval meeting Sign In to view filing content.
Apr 18, 2024	PR announcing liquidation and redemption of public shares Sign In to view filing content.

Nocturne Acquisition Corporation

Sign in to view more

Structure

Team

Advisors

Filings

Shareholders